Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine-Reference-Cited by-同舟云学术

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine

Author:

Yong Xiaolan¹,Liu Jun²,Zeng Ying³⁴,Nie Jing²,Cui Xuelian⁵,Wang Tao⁵,Wang Yilin⁵,Chen Yiyong⁵,Kang Wei³⁴,Yang Zhonghua³⁴,Liu Yan⁵⁶

Affiliation:

1. Phase I Clinical Trial Center, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China

2. Pulmonary and Critical Care Medicine, Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District), Chongqing, China

3. Department of Medicine and Registration, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, China

4. Department of Medicine and Registration, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, China

5. Department of Medicine, Chongqing Medleader Bio-Pharm Co. Ltd, Chongqing, China

6. College of Pharmacy, Chongqing Medical University, Chongqing, China

Funder

Key Program of the Yantai Science & Technology

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

Reference35 articles.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献